Publications

Cardiovascular and Diabetes

Cardiovascular and Diabetes 
Gaw JR, Crowley S, Monagle P, Jones S, Newall F (2013) The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. Thromb Res;132(1):26-31
CLICK HERE TO READ
Aristides M, Weston A, Fitzgerald P, Le Reun C, Maniadakis N. 2004. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multi-country application of a discrete choice experiment. Value in Health 7:442–454.
CLICK HERE TO READ
Tilden D, Pascoe K, Higashi MK, Marelli C, Kennedy L, Scheijbeler H, Aristides M. Towards a modelled economic evaluation to identify the optimal population for screening of coronary artery disease. pcv78, Saturday, October 28, 2006, ISPOR ninth annual European congress, Copenhagen, Denmark)
CLICK HERE TO READ
Ashley ED, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J.  Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options.  Pharmacotherapy. 2012 32, 890
CLICK HERE TO READ
Tahami Monfared AA, O’Sullivan AK, Rotstein C, Papadopoulos G.  Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada.  Can J Infect Dis Med Microbiol 2012; 23(2):59–64.
CLICK HERE TO READ
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673
CLICK HERE TO READ
Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G. Comparative Survival and Cost of Therapy: Posaconazole vs. Standard Antifungals in Treatment of Invasive, Refractory Aspergillosis. Curr Med Res Opin, 2010 Oct 26 (10): 2457-64
CLICK HERE TO READ
Kielhorn A, Rubbert A, Porter D, De Vita S, Brown B, Aristides M, Aultman R, Jost F. Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-european analysis. (par10, Saturday, May 20, 2006, ISPOR eleventh annual international meeting, Philadelphia, pa)
CLICK HERE TO READ
O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole Versus Fluconazole in the Prevention of Invasive Fungal Infections Among Patients with Graft-versus-Host Disease in the US. Am J Health Syst Pharm Jan 15 2012.
CLICK HERE TO READ
Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
Oncology. 2010;78(3-4):172-80. Epub 2010 Apr 23.
CLICK HERE TO READ
Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Danna R, Papadopoulos G. The Economic Costs to United States Hospitals of Invasive Fungal Infections Transplant Patients.  Am J Infect Control 2010 Oct 19
CLICK HERE TO READ
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673
CLICK HERE TO READ
Aristides M, Kotchie R, Nielsen S, Townsend C, Valentine WJ, Scheijbeler H. Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting. (pdb23, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland)
CLICK HERE TO READ
Aristides M, Kotchie R, Nielsen S, Aagren M, Valentine W, Goodall G. Cost-effectiveness of insulin detemir versus nph for type 1 diabetes patients in an Italian setting. a meta-analysis. (pdb20, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland).
CLICK HERE TO READ
Brown B, Odeyemi IA, Christova L, Aristides M, Tilden D. Using the general practice research database to estimate the incidence, prevalence and management of hyperhidrosis in the United Kingdom. (psn1, Sunday, November 06, 2005, ISPOR eighth European congress, Florence, Italy).
CLICK HERE TO READ
Crowley S, Tognarini D, Desmond P, Lees M, Saal G (2002) Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol. 2002;17(2):153-64.
CLICK HERE TO READ
Shalom B, Langford J, Berry G, Collins D, Lauchlan R, Stewart K, Aristides M, Dobson M. 2000. Economic impact of increased clinical intervention rates in community pharmacy – a randomised trial of the effect of educational and a professional allowance. Pharmacoeconomics 18:459–468.
CLICK HERE TO READ

Central Nervous System

Central Nervous System 
Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88.
CLICK HERE TO READ
Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine Frequency and Health Utilities: Findings from a multi-site survey. Value In Health 2008, 11, 2, 315-321
CLICK HERE TO READ
Cottrell S, Allen E, Pascoe K, Sullivan T, LeReun C, Brown J, Lorenzo M, Aristides M. Preference and willingness-to-pay study to assess the value of atomoxetine using discrete choice analysis: uk parents perspective. (pmh48, Monday, May 28, 2007, ISPOR twelfth annual international meeting, arlington, va, usa)
CLICK HERE TO READ
Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine Frequency and Health Utilities: Findings from a multi-site survey. Value In Health 2008, 11, 2, 315-321
CLICK HERE TO READ
Diamond M, Dahlöf C, Papadopoulos G, Neto, Wu S-C,. Topiramate improves health-related quality of life when used to prevent migraine.  Headache 45, 1023-1030, 2005
CLICK HERE TO READ
Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88.
CLICK HERE TO READ
Stahl, SM, Markowitz, JS, Papadopoulos, G, Sadik, K.  Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease.  Current Medical Research and Opinion 20(4) 517-524, 2004
CLICK HERE TO READ
Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost effectiveness of migraine prevention: the case of topiramate in the United Kingdom. Cephalalgia 26, 1473-82, 2006
CLICK HERE TO READ
Markowitz JS, Gutterman E, Papadopoulos G. Health Related Quality of Life Among Caregivers with persons with Alzheimer’s Disease.  Alzheimers Disease and Associated Disorders 17, 209-214, 2003
CLICK HERE TO READ
Markowitz JS, Gutterman EM, Lilieneld S, Papadopoulos G. Sleep-Related Outcomes in Persons with Mild to Moderate Alzheimer's disease in a Placebo-Controlled Trial of Galantamine.  Sleep 26(5), 602-606, 2003
CLICK HERE TO READ
Caro JJ, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, Torfs K. To What Degree Does Cognitive Impairment in Alzheimer’s Disease Predict Dependence of Patients on Caregivers. BMC Neurology 2:6; 2002
CLICK HERE TO READ
Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G for the AHEAD Study Group.  Economic evaluation of galantamine for the treatment of mild to moderate Alzheimer’s disease in the United States Current Therapeutics 25(6), 1806-25, 2003
CLICK HERE TO READ
Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. CMRO 22, 6, 1021-1029, 2006
CLICK HERE TO READ
Tilden D, Aristides M, Meddis D, Burns T. 2002. An economic evaluation of quetiapine and haloperidol in the treatment of schizophrenic patients partially responsive to previous antipsychotics. Clinical Therapeutics 24:1648–1667.
CLICK HERE TO READ

Economic modelling and Cost-effectiveness

Economic modelling and Cost-effectiveness 
Gaw JR, Crowley S, Monagle P, Jones S, Newall F (2013) The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring. Thromb Res;132(1):26-31
CLICK HERE TO READ
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673
CLICK HERE TO READ
Ashley ED, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy. 2012 32, 890
CLICK HERE TO READCLICK HERE TO READ
Tahami Monfared AA, O’Sullivan AK, Rotstein C, Papadopoulos G. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol 2012; 23(2):59–64.
CLICK HERE TO READ
O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G. Cost-Effectiveness of Posaconazole Versus Fluconazole in the Prevention of Invasive Fungal Infections Among Patients with Graft-versus-Host Disease in the US. Am J Health Syst Pharm Jan 15 2012.
CLICK HERE TO READ
Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A.
Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
Oncology. 2010;78(3-4):172-80. Epub 2010 Apr 23.
CLICK HERE TO READ
Shih ST, Crowley S, Sheu JC (2010) Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc;109(1):39-55.
CLICK HERE TO READ
Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G. Comparative Survival and Cost of Therapy: Posaconazole vs. Standard Antifungals in Treatment of Invasive, Refractory Aspergillosis. Curr Med Res Opin, 2010 Oct 26 (10): 2457-64
CLICK HERE TO READ
Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Danna R, Papadopoulos G. The Economic Costs to United States Hospitals of Invasive Fungal Infections Transplant Patients. Am J Infect Control 2010 Oct 19
CLICK HERE TO READ
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC. Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health. 2009, 12, 5, 666-673
CLICK HERE TO READ
Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008 May-Jun;11(3):376-88.
CLICK HERE TO READ
Cottrell S, Walker M, Scheijbeler H, Christova L, Hertel N, Hass B, Behrens M, Roux E, Amonkar M, Aristides M. 2008. Impact of brain metastases on health care costs associated with the management of patients with metastatic breast cancer in France and Germany. Eur J Cancer. 6(7):176.
CLICK HERE TO READ
Aristides M, Kotchie R, Nielsen S, Townsend C, Valentine WJ, Scheijbeler H. Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in a polish setting. (pdb23, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland)
CLICK HERE TO READ
Geary U, Lewis G, Aultman R, Aristides M.A cost utility analysis of maintenance rituximab for the treatment of relapsed/refractory follicular non hodgkins lymphoma (nhl) in the uk. (pcn46, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland).
CLICK HERE TO READ
Tilden D, Pascoe K, Higashi MK, Marelli C, Kennedy L, Scheijbeler H, Aristides M. Towards a modelled economic evaluation to identify the optimal population for screening of coronary artery disease. pcv78, Saturday, October 28, 2006, ISPOR ninth annual European congress, Copenhagen, Denmark)
CLICK HERE TO READ
Kielhorn A, Rubbert A, Porter D, De Vita S, Brown B, Aristides M, Aultman R, Jost F. Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-european analysis. (par10, Saturday, May 20, 2006, ISPOR eleventh annual international meeting, Philadelphia, pa)
CLICK HERE TO READ
Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J. Cost effectiveness of migraine prevention: the case of topiramate in the United Kingdom. Cephalalgia 26, 1473-82, 2006
CLICK HERE TO READ
Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Review of Pharmacoeconomics and Outcomes Research 4(1):27–38.
CLICK HERE TO READ
Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G for the AHEAD Study Group.  Economic evaluation of galantamine for the treatment of mild to moderate Alzheimer’s disease in the United States Current Therapeutics 25(6), 1806-25, 2003
CLICK HERE TO READ

Meta-analyses and HTA related

Meta-analyses and HTA related 
Stahel, J.L. Pujol, G. Scagliotti, J. Vansteenkiste, N. Thatcher, C. Manegold, N. van Zandwijk, JY Douillard, M. Aristides Analysis of survival outcomes: Sub-Analysis of Gemcitabine plus Cisplatin (GC) compared with other Cisplatin-containing regimens in the Treatment of Advanced Non-Small-Cell Lung Cancer. R. International Congress of on Anti Cancer Treatment (ICACT). The congress is scheduled from 5th to 8th February 2008 in Paris.
CLICK HERE TO READ
Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?
App. Health Econ Health Policy. 2015: 13(3); 291-302.
CLICK HERE TO READ
Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007, ISPOR tenth annual european congress, Dublin, Ireland)
CLICK HERE TO READ
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80.
CLICK HERE TO READ
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80.
CLICK HERE TO READ
Dunt DR, Crowley S, Day NA. Is prevention really better than cure? Parameters of the debate and implications for program evaluation design. Health Promot. Int. (1995) 10 (4): 325-334
CLICK HERE TO READ
Smith CS, Crowley S (1995). Labor force planning issues for allied health in Australia. J Allied Health; 24(4):249-65.
CLICK HERE TO READ
Aristides M, Mitchell A. 1994. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics 6:196–201.
CLICK HERE TO READ
Richardson J, Crowley S. (1994) Optimum alcohol taxation: balancing consumption and external costs. Health Econ;3(2):73-87.
CLICK HERE TO READ
Balding C, Crowley S, Collopy BT.ACHS Care Evaluation Program Hospital-Wide Clinical Indicator Seminar. Aust Clin Rev. 1990;10(2):80-2
CLICK HERE TO READ

Oncology

Oncology 
Aristides Mike, Barlev Arie, Barber Beth, Gijsen Merel, Quinn Casey. Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom. Health and Quality of Life Outcomes. 2015, 13:181
DOI: 10.1186/s12955-015-0377-3.
CLICK HERE TO READ
Shih ST, Crowley S, Sheu JC (2010) Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc;109(1):39-55.
CLICK HERE TO READ
Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007
CLICK HERE TO READ
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80.
CLICK HERE TO READ
Aristides M, von der Maase H, Roberts T, Brown A, Kielhorn A, Bhalla S. 2005. Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer. European Journal of Cancer Care 14:141–2.
CLICK HERE TO READ
Cottrell S, Walker M, Scheijbeler H, Christova L, Hertel N, Hass B, Behrens M, Roux E, Amonkar M, Aristides M. 2008. Impact of brain metastases on health care costs associated with the management of patients with metastatic breast cancer in France and Germany. Eur J Cancer. 6(7):176.
CLICK HERE TO READ
Geary U, Lewis G, Aultman R, Aristides M.A cost utility analysis of maintenance rituximab for the treatment of relapsed/refractory follicular non hodgkins lymphoma (nhl) in the uk. (pcn46, Saturday, October 20, 2007, ISPOR tenth annual European congress, Dublin, Ireland).
CLICK HERE TO READ
Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Review of Pharmacoeconomics and Outcomes Research 4(1):27–38.
CLICK HERE TO READ
Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?
App. Health Econ Health Policy. 2015: 13(3); 291-302.
CLICK HERE TO READ
Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N. 2003. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. European Journal of Health Economics 4(3): 216–221.
CLICK HERE TO READ

Utility and Preference Studies

Utility and Preference Studies 
Stahel, J.L. Pujol, G. Scagliotti, J. Vansteenkiste, N. Thatcher, C. Manegold, N. van Zandwijk, JY Douillard, M. Aristides Analysis of survival outcomes: Sub-Analysis of Gemcitabine plus Cisplatin (GC) compared with other Cisplatin-containing regimens in the Treatment of Advanced Non-Small-Cell Lung Cancer. R. International Congress of on Anti Cancer Treatment (ICACT). The congress is scheduled from 5th to 8th February 2008 in Paris.
CLICK HERE TO READ
Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?
App. Health Econ Health Policy. 2015: 13(3); 291-302.
CLICK HERE TO READ
Jenkins A, Aristides M, Liepa AM, Relf C, Feilding B. Treatment patterns for patients with glioblastoma multiforme (GBM) in Germany. (pcn59, Saturday, October 20, 2007, ISPOR tenth annual european congress, Dublin, Ireland)
CLICK HERE TO READ
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80.
CLICK HERE TO READ
Dunt DR, Crowley S, Day NA. Is prevention really better than cure? Parameters of the debate and implications for program evaluation design. Health Promot. Int. (1995) 10 (4): 325-334
CLICK HERE TO READ
Smith CS, Crowley S (1995). Labor force planning issues for allied health in Australia. J Allied Health; 24(4):249-65.
CLICK HERE TO READ
Aristides M, Mitchell A. 1994. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics 6:196–201.
CLICK HERE TO READ
Richardson J, Crowley S. (1994) Optimum alcohol taxation: balancing consumption and external costs. Health Econ;3(2):73-87.
CLICK HERE TO READ
Balding C, Crowley S, Collopy BT.ACHS Care Evaluation Program Hospital-Wide Clinical Indicator Seminar. Aust Clin Rev. 1990;10(2):80-2
CLICK HERE TO READ

Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.

ADDRESS

32 Mitchell St, McMahon's Pt NSW 2060

GET IN TOUCH

4 + 14 =